Candel Therapeutics, Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.22 | — | — | Miss |
| Q12026 FY2026 | $-0.22 | $-0.14 | +36.4% | Beat |
| 2026-05-12 | $-0.30 | — | — | Miss |
| 2026-03-12 | $-0.24 | — | — | Miss |
Back to CADL overview · CADL holders · CADL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.